Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





HEXACHLOROCYCLOPENTADIENE								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 77-47-4; **Chemical Formula:** C5Cl6 .
No previous OSHA limit existed for hexachlorocyclopentadiene. The Agency proposed to establish a 0.01-ppm 8-hour TWA limit for this substances, based on the ACGIH (1986/Ex. 1-3) recommendation; NIOSH (Ex. 8-47, Table N1) concurred with this proposal, and the final rule adds this limit to the Z table. Hexachlorocyclopentadiene is a yellow to amber-colored, non flammable liquid with a pungent odor.
Hexachlorocyclopentadiene has a high order of acute toxicity in laboratory animals. Rabbits, mice, rats, and guinea pigs died from inhaling 89.5 percent of the vapor in air (Treon, Cleveland, and Cappel 1955/Ex. 1-497). In 150 daily exposures of seven hours each, rabbits, rats, and guinea pigs survived concentrations of 0.15 ppm, but a similar exposure was fatal to four of five mice. At approximately twice this concentration, mice, rats, and most rabbits died by or before the 25th exposure, but guinea pigs survived 30 exposures. The hexachlorocyclopentadiene vapors caused tearing, labored respiration, and, at high concentrations, tremors. Treon and associates (1955/Ex. 1-497) observed degenerative changes in the brain, heart, liver, adrenal glands, and kidneys, and pulmonary irritation occurred in all species, even at the lowest concentration of 0.15 ppm. At higher concentrations, pulmonary edema, hyperemia, necrotizing bronchitis, and bronchiolitis were observed (Treon, Cleveland, and Cappel 1955/Ex. 1-497).
In humans, there are few data concerning hexachlorocyclopentadiene’s toxicity. Irritation is known to occur, but the intolerable odor and eye irritation associated with exposure to this substance have discouraged prolonged exposures (McGilvray 1971, as cited in ACGIH 1986/Ex. 1-3, p. 300).
The New Jersey Department of Public Health (Exs. 144, 144A) urged OSHA to establish a PEL for hexachlorocyclopentadiene on the basis of EPA’s IRIS data. The use of this approach is discussed in Section VI.A of the preamble.
The proposed TWA PEL of 0.01 ppm for this severely toxic substance is about 10 times below the level associated with systemic damage and pulmonary irritation in experimental animals. In the absence of any limit on exposure, OSHA finds that employees are at significant risk of intense eye and pulmonary irritation and multiple organ damage; the Agency considers these effects to be material impairments of health and functional capacity. To substantially reduce these risks, OSHA is establishing an 8-hour TWA limit of 0.01 ppm for hexachlorocyclopentadiene.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue